Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03371017
Recruitment Status : Recruiting
First Posted : December 13, 2017
Last Update Posted : March 13, 2019
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche

Brief Summary:
This study will evaluate the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple-negative breast cancer (TNBC).

Condition or disease Intervention/treatment Phase
Triple Negative Breast Neoplasms Drug: Atezolizumab Drug: Placebo Drug: Gemcitabine Drug: Capecitabine Drug: Carboplatin Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 350 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase III, Randomised, Double-Blind, Placebo-Controlled, Multicentre Study Of The Efficacy And Safety Of Atezolizumab Plus Chemotherapy For Patients With Early Relapsing Recurrent (Inoperable Locally Advanced Or Metastatic) Triple-Negative Breast Cancer
Actual Study Start Date : January 11, 2018
Estimated Primary Completion Date : July 31, 2019
Estimated Study Completion Date : January 31, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Atezolizumab
Participants will receive Atezolizumab on day 1 of each 3-week treatment cycle
Drug: Atezolizumab

Atezolizumab will be administered, 1200 mg by IV infusion with :

gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle


Drug: Gemcitabine
Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle

Drug: Capecitabine
Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle

Drug: Carboplatin
Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle

Placebo Comparator: Placebo
Participants will receive Placebo on day 1 of each 3-week treatment cycle
Drug: Placebo

Placebo will be administered, 1200 mg by IV infusion with :

gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle or with capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle


Drug: Gemcitabine
Gemcitabine 1000 mg/m2, followed by carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle

Drug: Capecitabine
Capecitabine 1000 mg/m2, twice daily orally on Days 1 to 14, followed by a 7-day rest period in each 3-week treatment cycle

Drug: Carboplatin
Carboplatin target area under the curve (AUC) 2 mg/ml/min, both administered by IV infusion on Days 1 and 8 of each 3-week treatment cycle




Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: Randomization: 30 months post FPI ]

Secondary Outcome Measures :
  1. Proportion of patients alive 12 months [ Time Frame: Randomization; 12 months post randomization ]
  2. Proportion of patients alive 18 months [ Time Frame: Randomization; 18 months post randomization ]
  3. Progression-free survival (PFS) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) [ Time Frame: Randomisation to the first occurrence of disease progression or death (through the end of study, approximately 36 months) ]
  4. Objective response rate (ORR), defined as the proportion of patients with an objective response, defined as a complete response (CR) or a partial response (PR), as determined by the investigator according to RECIST 1.1 [ Time Frame: Baseline; every 8 weeks for the first 12 months after randomisation, and every 12 weeks thereafter until PD, withdrawal of consent, death, or study termination (approximately 36 months) ]
  5. Duration of objective response (DoR) as determined by the investigator according to RECIST 1.1 [ Time Frame: Time from the first occurrence of a documented objective response to disease progression or death (through the end of study, approximately 36 months) ]
  6. Clinical benefit rate (CBR), defined as the proportion of patients with a CR or a PR or stable disease as determined by the investigator according to RECIST 1.1 [ Time Frame: 8 weeks for the first 12 months after treatment initiation and every 12 weeks thereafter until disease progression (through the end of study, approximately 36 months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed triple negative breast cancer(TNBC) that is either locally recurrent, inoperable and cannot be treated with curative intent or is metastatic
  • Documented disease progression occurring within 12 months from the last treatment with curative intent
  • Have not received prior chemotherapy or targeted systemic therapy for their locally advanced inoperable or metastatic recurrence. Prior radiation therapy for recurrent disease is permitted
  • Measurable or non-measurable disease, as defined by RECIST 1.1
  • Availability of a representative formalin-fixed paraffin-embedded (FFPE) tumour block (preferred) or at least 25 unstained slides with an associated pathology report, if available
  • Eastern Cooperative Oncology Group performance status 0-1
  • Life expectancy ≥ 12 weeks
  • Adequate haematologic and end-organ function
  • Negative human immunodeficiency virus (HIV) test ---Negative hepatitis B surface antigen (HBsAg) test at screening
  • Negative total hepatitis B core antibody (HBcAb) test at screening, or positive HBcAb test followed by a negative hepatitis B virus (HBV) DNA test at screening
  • The HBV DNA test will be performed only for patients who have a positive HBcAb test
  • Negative hepatitis C virus (HCV) antibody test at screening, or positive HCV antibody test followed by a negative HCV RNA test at screening.
  • Women of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of ≤1% per year during the treatment period and for at least 5 months after the last dose of study treatment
  • Men must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agree to refrain from donating sperm

Exclusion Criteria:

  • Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for > 2 weeks prior to randomisation
  • Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases.
  • Symptomatic or rapid visceral progression
  • No prior treatment with an anthracycline and taxane
  • History of leptomeningeal disease
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently) (patients with indwelling catheters such as PleurX® are allowed)
  • Uncontrolled tumour-related pain
  • Uncontrolled or symptomatic hypercalcemia
  • Malignancies other than TNBC within 5 years prior to randomisation)
  • Significant cardiovascular disease, within 3 months prior to randomisation, unstable arrhythmias, or unstable angina
  • Presence of an abnormal ECG
  • Severe infection requiring oral or IV antibiotics within 4 weeks prior to randomisation, including but not limited to hospitalization for complications of infection, bacteraemia, or severe pneumonia.
  • Current treatment with anti-viral therapy for HBV.
  • Major surgical procedure within 4 weeks prior to randomisation or anticipation of the need for a major surgical procedure during the course of the study other than for diagnosis
  • Treatment with investigational therapy within 28 days prior to randomisation
  • Pregnant or lactating, or intending to become pregnant during or within 5 months after the last dose of study treatment

Exclusion Criteria Related to Atezolizumab:

  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanised antibodies or fusion proteins
  • Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulation
  • History of autoimmune disease
  • Prior allogeneic stem cell or solid organ transplantation
  • History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e. bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest computerised tomography (CT) scan History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
  • Active tuberculosis
  • Receipt of a live, attenuated vaccine within 4 weeks prior to randomisation or anticipation that a live, attenuated vaccine will be required during atezolizumab/placebo treatment or within 5 months after the last dose of atezolizumab/placebo
  • Prior treatment with CD137 agonists, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway targeting agents
  • Treatment with systemic immunostimulatory agents (including but not limited to interferons or interleukin [IL]-2) within 4 weeks or five half-lives of the drug (whichever is longer) prior to randomisation
  • Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomisation, or anticipated requirement for systemic immunosuppressive medications during the trial

Exclusion Criteria Related to Capecitabine:

  • Inability to swallow pills
  • Malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, or ulcerative colitis
  • Known dihydropyrimidine dehydrogenase (DPD) deficiency or history of severe and unexpected reactions to fluoropyrimidine therapy in patients selected to receive capecitabine

Exclusion Criteria Related to Carboplatin/Gemcitabine:

-Hypersensitivity to platinum containing compounds or any component of carboplatin or gemcitabine drug formulations in patients selected to receive carboplatin and Gemcitabine


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03371017


Contacts
Layout table for location contacts
Contact: Reference Study ID Number: MO39193 www.roche.com/about_roche/roche_worldwide.htm 888-662-6728 (U.S. and Canada) global-roche-genentech-trials@gene.com

  Hide Study Locations
Locations
Layout table for location information
United States, Florida
Florida Cancer Specialists - Fort Myers (Broadway) Recruiting
Fort Myers, Florida, United States, 33916
Florida Cancer Specialists & Research Institute Recruiting
Saint Petersburg, Florida, United States, 33705
United States, Georgia
Northwest Georgia Oncology Centers PC - Marietta Recruiting
Marietta, Georgia, United States, 30060
United States, Missouri
HCA Midwest Division Recruiting
Kansas City, Missouri, United States, 64132
United States, New Jersey
The Valley Hospital Recruiting
Paramus, New Jersey, United States, 07652
United States, Pennsylvania
Magee-Woman's Hospital; UPMC Pinnacle Cancer Center Recruiting
Harrisburg, Pennsylvania, United States, 17109
Magee-Woman's Hospital Recruiting
Pittsburgh, Pennsylvania, United States, 15213
United States, Tennessee
Tennessee Oncology; Sarah Cannon Research Institute Recruiting
Nashville, Tennessee, United States, 37203
United States, Virginia
Inova Schar Cancer Institute Recruiting
Falls Church, Virginia, United States, 22042
Algeria
Centre hospitalo-univerisitaire de Rouiba;Service d'oncologie médicale Not yet recruiting
Algiers, Algeria, 16016
Centre Anti Cancer Beau-fraisier;Service d'oncologie médicale Not yet recruiting
Algiers, Algeria, 16340
CHU Constantine; Service d'Oncologie Médicale Not yet recruiting
Constantine, Algeria, 25000
Bosnia and Herzegovina
University Clinical Center of the Republic of Srpska Recruiting
Banja Luka, Bosnia and Herzegovina, 78000
Clinic of Oncology, University Clinical Center Sarajevo Recruiting
Sarajevo, Bosnia and Herzegovina, 7100
Brazil
Hospital Araujo Jorge; Departamento de Ginecologia E Mama Active, not recruiting
Goiania, GO, Brazil, 74605-070
Hospital do Cancer de Pernambuco - HCP Active, not recruiting
Recife, PE, Brazil, 50040-000
Hospital Sao Vicente de Paulo Recruiting
Passo Fundo, RS, Brazil, 99010-080
Hospital Nossa Senhora da Conceicao Recruiting
Porto Alegre, RS, Brazil, 91350-200
Hospital Perola Byington Active, not recruiting
Sao Paulo, SP, Brazil, 01317-000
Cuba
Hospital Hermanos Ameijeiras Recruiting
La Habana, Cuba, 10300
Instituto Nacional de Oncología y Radiología (INOR) Recruiting
La Habana, Cuba, 10400
Finland
Helsinki University Central Hospital; Dept of Oncology Recruiting
Helsinki, Finland, 00029
Tampere University Hospital; Dept of Oncology Recruiting
Tampere, Finland, 33520
Turku Uni Central Hospital; Oncology Clinics Recruiting
Turku, Finland, 20520
France
Centre Georges-François Lecler; Ctr de Lutte Contre le Canc Recruiting
Dijon, France, 21034
Centre Leon Berard; Oncologie Genetique Active, not recruiting
Lyon, France, 69373
Institut Paoli-Calmettes; Oncologie Medicale 1 Recruiting
Marseille Cedex 09, France, 13273
Centre Régional de Lutte Contre Le Cancer Val D'aurelle Paul Lamarque Recruiting
Montpellier, France, 34298
INSTITUT CURIE_SITE PARIS - Service d'Oncologie Médicale. Active, not recruiting
Paris, France, 75005
Centre Eugene Marquis; Service d'oncologie Recruiting
Rennes, France, 35042
Centre Alexis Vautrin; Oncologie Medicale Recruiting
Vandoeuvre Les Nancy, France, 54511
IGR Recruiting
Villejuif, France, 94800
Germany
Praxisklinik Krebsheilkunde für Frauen / Brustzentrum (Dres. Kittel/Klare) Withdrawn
Berlin, Germany, 10367
Universitätsklinikum "Carl Gustav Carus"; Frauenheilkunde und Geburtshilfe Recruiting
Dresden, Germany, 01307
Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum Recruiting
Essen, Germany, 45136
Klinikum Frankfurt Höchst GmbH; Klinik für Gynäkologie und Geburtshilfe Recruiting
Frankfurt, Germany, 65929
Universitätsklinikum Halle (Saale); Universitätsklinik Und Poliklinik Für Gynäkologie Recruiting
Halle, Germany, 06120
Onkologische Schwerpunktpraxis Eppendorf Recruiting
Hamburg, Germany, 20249
Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe Active, not recruiting
Hannover, Germany, 30625
Nationales Centrum für Tumorerkrankungen (NCT) ; Gyn. Onk. Frauenklinik; Uniklinikum Heidelberg Active, not recruiting
Heidelberg, Germany, 69120
Kliniken der Stadt Köln gGmbH Krankenhaus Holweide; Brustzentrum Not yet recruiting
Köln, Germany, 51067
Gemeinschaftspraxis Prof. Dr.med. Christoph Salat und Dr.med. Oliver J. Stötzer Active, not recruiting
München, Germany, 80638
Caritas-Krankenhaus St. Josef; Klinik für Frauenheilkunde und Geburtshilfe Recruiting
Regensburg, Germany, 93053
Hungary
Szent Margit Hospital Active, not recruiting
Budapest, Hungary, 1032
Orszagos Onkologiai Intezet; B Belgyogyaszati Osztaly Active, not recruiting
Budapest, Hungary, 1122
Uzsoki Utcai Korhaz Recruiting
Budapest, Hungary, 1145
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz;Sugarterapias Klinikai Onkologiai Intez Recruiting
Miskolc, Hungary, 3526
Pécsi Tudományegyetem Áok; Onkoterapias Intezet Active, not recruiting
Pecs, Hungary, 7624
Italy
Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale Active, not recruiting
Napoli, Campania, Italy, 80131
Azienda Ospedaliero Universitaria San Martino Recruiting
Genova, Liguria, Italy, 16132
Ospedale San Raffaele S.r.l. Recruiting
Milano, Lombardia, Italy, 20132
Irccs Istituto Europeo Di Oncologia (IEO); Ricerca Di Senologia Medica Recruiting
Milano, Lombardia, Italy, 20141
Ospedale San Gerardo Recruiting
Monza, Lombardia, Italy, 20052
Fondazione Del Piemonte Per L'oncologia Ircc Di Candiolo; Dipartimento Oncologico Active, not recruiting
Candiolo, Piemonte, Italy, 10060
Ospedale Antonio Perrino; Oncologia Medica Active, not recruiting
Brindisi, Puglia, Italy, 72100
Azienda Ospedaliero-Universitaria Careggi; SOD Radioterapia Recruiting
Firenze, Toscana, Italy, 50134
IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Seconda Recruiting
Padova, Veneto, Italy, 35128
Kazakhstan
Kazakh Scientific Research Institution Of Oncology and Radiology; Chemotherapy department Active, not recruiting
Almaty, Kazakhstan, 050022
Almaty Cancer Hospital; Chemotherapy department Not yet recruiting
Almaty, Kazakhstan
Oncology centre of Astana; Chemotherapy department Not yet recruiting
Astana, Kazakhstan, 010000
Korea, Republic of
Seoul National University Bundang Hospital Recruiting
Gyeonggi-do, Korea, Republic of, 13620
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of, 03080
Samsung Medical Center - Neurology Active, not recruiting
Seoul, Korea, Republic of, 6351
Mexico
Centro Medico Dalinde Recruiting
Cdmx, Mexico CITY (federal District), Mexico, 06760
Instituto Nacional de Cancerologia; Oncology Active, not recruiting
Distrito Federal, Mexico, 14080
Consultorio de Medicina Especializada; Dentro de Condominio San Francisco Recruiting
Mexico City, Mexico, 03100
Montenegro
Clinical Center of Montenegro; Clinic for Oncology and Radiotherapy Recruiting
Podgorica, Montenegro, 81000
Morocco
Centre Hospitalier Universitaire Mohamed VI; Oncologie-Hématologie Recruiting
Marrakech, Morocco, 40000
Clinique specialise Menara; Oncology Medical Recruiting
Marrakech, Morocco, 40000
Institut National D'oncologie Sidi Med Benabdellah Recruiting
Rabat, Morocco, 6213
Panama
Centro Hemato Oncologico Panama Recruiting
Panama, Panama, 0832
Russian Federation
Moscow City Oncology Hospital #62 Active, not recruiting
Moscovskaya Oblast, Moskovskaja Oblast, Russian Federation, 143423
FSBI "National Medical Research Center of Oncology N.N. Blokhin" Active, not recruiting
Moscow, Russian Federation, 115478
S-Pb clinical scientific practical center of specialized kinds of medical care (oncological) Terminated
Saint-Petersburg, Russian Federation, 197758
City Clinical Oncology Dispensary, SPb SBIH CCOD Active, not recruiting
Saint-Petersburg, Russian Federation, 198255
Serbia
Clinical Hospital Center Bezanijska kosa; Clinic for Oncology Recruiting
Belgrade, Serbia, 11000
Institute of Oncology and Radiology of Serbia Recruiting
Belgrade, Serbia, 11000
Clinical Centre Nis, Clinic for Oncology Active, not recruiting
Nis, Serbia, 18000
Oncology Institute of Vojvodina Recruiting
Sremska Kamenica, Serbia, 21204
Singapore
National University Hospital; National University Cancer Institute, Singapore (NCIS) Recruiting
Singapore, Singapore, 119228
National Cancer Centre; Medical Oncology Recruiting
Singapore, Singapore, 169610
South Africa
Cape Town Oncology Trials Not yet recruiting
Cape Town, South Africa, 7570
The Oncology centre,Durban; Clinical Oncology Not yet recruiting
Durban, South Africa, 4001
Wits Clinical Research; Charlotte Maxeke Johannesburg Academic Hospital Recruiting
Johannesburg, South Africa, 2193
Medical Oncology Centre of Rosebank; Oncology Recruiting
Johannesburg, South Africa, 2196
University of Pretoria Oncology Department; Medical Oncology Recruiting
Pretoria, South Africa, 0002
Private Oncology Centre Recruiting
Pretoria, South Africa, 0081
Spain
Hospital de Cruces; Servicio de Oncologia Recruiting
Bilbao, Vizcaya, Spain, 48903
Hospital Universitari Vall d'Hebron; Oncology Active, not recruiting
Barcelona, Spain, 08035
Hospital General Universitario Gregorio Marañon; Servicio de Oncologia Active, not recruiting
Madrid, Spain, 28007
Hospital Ramon y Cajal; Servicio de Oncologia Active, not recruiting
Madrid, Spain, 28034
Hospital Clinico Universitario Virgen de la Victoria; Servicio de Oncologia Recruiting
Malaga, Spain, 29010
Hospital Clínico Universitario de Valencia; Servicio de Oncología Recruiting
Valencia, Spain, 46010
Turkey
Hacettepe University Medical Faculty; Department of Internal Medicine Recruiting
Ankara, Turkey, 06100
Ankara Oncology Hospital; Medical Oncology Department Recruiting
Ankara, Turkey, 06200
Ege University Medical Faculty; Medical Oncology Department Active, not recruiting
Bornova, İ̇zmi̇r, Turkey, 35100
Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi Recruiting
Edirne, Turkey, 22030
Medipol University MF; Oncology Department Recruiting
Istanbul, Turkey, 34214
Marmara University Pendik Training and Research Hospital; Medikal Onkoloji Recruiting
Istanbul, Turkey, 34890
Necmettin Erbakan University Meram Medical Faculty ; Internal Diseases Recruiting
Konya, Turkey, 42080
United Kingdom
Velindre Cancer Centre; Oncology Dept Recruiting
Cardiff, United Kingdom, CF14 2TL
University Hospital Coventry Recruiting
Coventry, United Kingdom, CV2 2DX
Western General Hospital; Edinburgh Cancer Center Active, not recruiting
Edinburgh, United Kingdom, EH4 2XU
Royal Lancaster Infirmary, Morecambe Bay Hospitals Nhs Trust Recruiting
Lancaster, United Kingdom, LA1 4RP
Barts Recruiting
London, United Kingdom, EC1M6BQ
Guys and St Thomas NHS Foundation Trust, Guys Hospital Recruiting
London, United Kingdom, SE1 9RT
Christie Hospital NHS Trust Active, not recruiting
Manchester, United Kingdom, M20 4BX
Mount Vernon Cancer Centre Recruiting
Northwood, United Kingdom, HA6 2RN
Royal Stoke University Hospital Recruiting
Stoke on Trent, United Kingdom, ST4 6QG
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Layout table for investigator information
Study Director: Clinical Trials Hoffmann-La Roche

Layout table for additonal information
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT03371017     History of Changes
Other Study ID Numbers: MO39193
2016-005119-42 ( EudraCT Number )
First Posted: December 13, 2017    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Triple Negative Breast Neoplasms
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Gemcitabine
Capecitabine
Carboplatin
Atezolizumab
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs